Cytokinetics analyst coverage

Author: fqgt

August undefined, 2024

WebAnalyst Coverage; Investor FAQ; IR/Media Contacts; Corporate Governance; Information Request; Email Alerts WebSep 28, 2024 · News Profile Analyst Coverage 5 Yr. Financials Dividends Adv. Charts Earnings Options Price History Events Insiders

Cytokinetics Announces Positive Topline Results of REDWOOD …

WebSep 28, 2024 · Cytokinetics Incorporated CYTK Competitors News Profile Analyst Coverage 5 Yr. Financials Dividends Adv. Charts Earnings Options Price History Events Insiders Cytokinetics Incorporated News... WebMay 24, 2024 · Below is a summary of how these 4 analysts rated Cytokinetics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … diabetic lactosefree smoothie

CYTK Cytokinetics Inc. Analyst Estimates MarketWatch

WebFeb 27, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK - Get Rating) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports.One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy … WebOur Corporate Responsibility Framework. Keep Patients at the Center of our Work. Continue to embed patient centricity across all stages of our business. Maintain strong … WebApr 5, 2024 · Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. INVESTORS & … diabetic lab once a year

CYTK Price Target 2024 Cytokinetics Analyst Ratings - MarketBeat

Baird Initiates Coverage of Pliant Therapeutics (PLRX) with ... - MSN

Web12 hours ago · Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and Neurocrine (NBIX – Research Report). Cytokinetics ... WebOct 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. cindy\u0027s taxes swift currentWebApr 6, 2024 · Analyst Price Forecast Suggests 12.99% Upside As of April 6, 2024, the average one-year price target for Broadcom is $696.81. The forecasts range from a low of $589.84 to a high of $787.50. diabeticlack of food

"WebMar 7, 2024 · Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Mizuho Posted by Defense World Staff on Mar 7th, 2024 Mizuho assumed coverage on shares of Cytokinetics ( NASDAQ:CYTK – Get... " - Cytokinetics analyst coverage

Cytokinetics analyst coverage

WebMar 31, 2024 · Mar. 31, 2024, 04:01 PM Over the past 3 months, 13 analysts have published their opinion on Cytokinetics (NASDAQ:CYTK) stock. These analysts are typically employed by large Wall Street banks and... WebJul 19, 2024 · SOUTH SAN FRANCISCO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results …

Did you know?

WebFor more in-depth coverage of Tesla Motors, ... Analyst Price Forecast Suggests 12.52% Upside. As of April 6, 2024, the average one-year price target for Tesla Motors is $203.14. The forecasts ... WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class …

Web12 hours ago · Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics ( CYTK – Research Report) and Neurocrine ( … WebMar 7, 2024 · Cytokinetics (CYTK) Analysts Prediction, Stock Forecast & Price Targets - Simply Wall St View Valuation Cytokinetics Future Growth Future criteria checks 0/6 Cytokinetics, Incorporated's earnings is forecasted to decline at 23.5% and its revenue is expected to decline at 46.6%.

WebApr 9, 2024 · Truist Financial initiated coverage on shares of Cytokinetics in a research note on Tuesday, December 20th. They issued a “buy” rating and a $60.00 target price for the company. Bank of America... WebNov 3, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.

WebMar 31, 2024 · SOUTH SAN FRANCISCO, Calif., March 31, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring …

WebApr 5, 2024 · According to analysts' consensus price target of $56.21, Cytokinetics has a forecasted upside of 60.7% from its current price of $34.99. Amount of Analyst … diabetic ladies cotton underwareWebMay 10, 2024 · Following the latest downgrade, the ten analysts covering Cytokinetics provided consensus estimates of US$17m revenue in 2024, which would reflect a painful … cindy\u0027s teesWebMar 31, 2024 · March 31, 2024 Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis. March 27, 2024 Cytokinetics Releases Inaugural Corporate Responsibility Report. March … diabetic lactose free meal planWebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth … diabetic lagerWeb1 day ago · Similarly, MAC has 32.06% upside from the recent share price of $9.92 if the average analyst target price of $13.10/share is reached, and analysts on average are expecting HR to reach a target ... diabetic lab results spreadsheetWebPer-Share Earnings, Actuals & Estimates Cytokinetics Inc. Quarterly Annual Actual Analyst Range Consensus 0.50 0.00 -0.50 -1.00 -1.50 CYTK will report Q1 earnings on … cindy\\u0027s teesWeb17 rows · Mar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference … cindy\\u0027s teddy bear daycare